Q3 beat; promising growth across the key offerings

30/10/24 -"bioMerieux’s Q3 organic sales were a beat. The double-digit growth was driven by a healthy contribution from both segments. While the 2024 guidance remained unchanged, investors rejoiced at the ..."

Executive summary
Conflict of interest

Pages

Language

English

Published on

30/10/24

Download

You may also be interested by these reports :

08/10/26

Demant

Our target price has increased due to a higher NAV and DCF, along with a 20% premium applied to our peer-based valuation metrics, excluding dividend ...

08/10/26

Sartorius Stedim Biotech

The TP increase reflects upgrades to our DCF and NAV (discussed above). The investment case remains compelling: consumables-led growth, the ...

08/10/26

PHILIPS

Beaten down, not broken.

05/10/26

Idea Kicker

When we last teased on Fresenius (BUY; Germany) in May 2025, the story was about slimming down: shedding Vamed, deconsolidating FMC and working the ...

EXECUTIVE SUMMARY

Updates

Pension Risks

Target & Opinion

Governance & Management

Business & Trends

Graphics : Momentum

Money Making

Graphics : MACD & Volumes

Debt

Graphics : Sensitivities

Valuation

Sector: Performance

DCF

Sector: Key data

NAV/SOTP

Sector: Ratios & Valorisation

Worth knowing

Sector: Peers

Financials

Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking

Trading in corporate shares

Analyst ownership

Advising of corporate (strategy, marketing, debt, etc)

Research paid for by corporate

Provision of corporate access paid for by corporate

Link between and a banking entity

Brokerage activity at AlphaValue